|
|
|
| Efficacy and safety of tenofovir for blocking hepatitis B virus intrauterine transmission |
| The Third People's Hospital of Shenzhen, Guangdong Province, 518000 |
|
|
|
|
Abstract To investigate the efficacy and safety of tenofovir for blocking hepatitis B virus intrauterine transmission of pregnant women. Methods: the data of 446 pregnant women with hepatitis B were conlected retrospectively. 446 women from January 2011 to December 2014 were given routine intervention in control group, and 591 pregnant women from January 2015 to December 2018 in observation group were given tenofovir from 24-28 gestational weeks. Serum HBV DNA load, perinatal adverse reaction rate, situation of neonatal growth and development (length, head circumference, and body mass) and rate of high infant viral load of infants in the two groups were observed. Results: There was no significant difference in serum HBV DNA load of women before treatment between the two groups (P>0.05). The serum HBV DNA load of women in the observation group before delivery was (3.21±0.14)×108 copy/ml, which was significant lower than that ((7.14±1.09)×108 copy/ml) of women in the control group (P＜0.05). The incidence of adverse reaction during the perinatal period of women in the observation group was 1.7%, which was significant lower than that (3.8%) of the control group (all P＜0.05). There were no significant different in the length, head circumference, and body mass of the newborns between the two groups (P>0.05). The positive rate of high viral load of newborns in the control group was 0.7%, which was significant higher than that (0%) in the observation group (P＜0.05). Conclusion: Tenofovir used for treating the pregnant women with hepatitis B during pregnancy can effectively reduce the rate of mother-to-child transmission of hepatitis viru B, reduce the high viral load of infants, and has little adverse effect on the fetus, which is worthy of clinical application.
|
|
|
|
|
|
|
|
|
